NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Ironwood Pharmaceuticals Inc is a small cap company (market value between $300 million and $2 billion) in the Drug Manufacturers - Specialty & Generic industry.
Ironwood Pharmaceuticals is a biotechnology company developing and commercializing therapies for gastrointestinal and rare diseases. The company commercializes LINZESS (linaclotide), a GC-C agonist approved for treating irritable bowel syndrome with constipation, chronic idiopathic constipation, and functional constipation in various markets through partnerships with AbbVie, AstraZeneca, and Astellas. It also advances apraglutide for short bowel syndrome through strategic partnerships.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Ironwood Pharmaceuticals Inc stock.
Undervalued: intrinsic value $13.01 per share, market price $3.50, margin of safety 73.1% (as of 2026-10-30).
Discounting its cash flows at 7.1% (average of 3 methods) values the shares at $13.01; the price of $3.50 is 73% below that value, and 82% of that value comes from beyond year five.
Leak Score: 85/100 on 10 of 12 signals (Strong Leak).
17 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
IRWD is undervalued (as of the 2026-10-30 close). Discounting its cash flows at 7.1% (average of 3 methods) values the shares at $13.01; the price of $3.50 is 73% below that value, and 82% of that value comes from beyond year five.
$13.01 per share (as of the 2026-10-30 close), against a market price of $3.50. That is a margin of safety of 73.1%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
85 out of 100, which we rate "Strong Leak", on 10 of 12 value investing signals.